Related Experiment Video
Updated: Jun 5, 2026
07:01
Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
Published on: August 19, 2025
Advances in proteomic techniques for biomarker discovery in COPD
Begoña Casado1, Maurizio Luisetti, Paolo Iadarola
1Quality and Safety Department, Nestlé Research Center, Nestec Ltd., Vers-chez-les-Blanc, 1000 Lausanne 26, Switzerland. begona.casado@rdls.nestle.com
Expert Review of Clinical Immunology
|December 18, 2010
Summary
Researchers are using advanced proteomic techniques to identify biomarkers for chronic obstructive pulmonary disease (COPD). These biomarkers could help predict disease progression and improve understanding of COPD mechanisms.
Area of Science:
- Pulmonary Medicine
- Proteomics
- Biomarker Discovery
Background:
- Chronic obstructive pulmonary disease (COPD) involves chronic lung inflammation and progressive functional decline.
- Accurate prognostic tools are crucial for understanding COPD development and progression.
- Proteomic techniques offer advanced methods for biomarker discovery in complex diseases.
Purpose of the Study:
- To investigate proteomic approaches for identifying potential biomarkers in COPD.
- To explore the utility of mass spectrometry-based techniques in COPD research.
- To advance the comprehension of COPD pathogenesis through molecular analysis.
Main Methods:
- Proteomic analysis of various lung-origin samples from COPD patients.
- Application of Liquid Chromatography-Mass Spectrometry (LC/MS) and 2D Gel Electrophoresis-Mass Spectrometry (2-DE/MS).
- Utilizing 2-DE as a primary method for quantitative proteomics in COPD research.
Main Results:
- Identification of molecules as potential biomarkers for COPD.
- Demonstration of LC/MS and 2-DE/MS applicability to COPD-related samples.
- Establishment of proteomic approaches for quantitative analysis of COPD biomarkers.
Conclusions:
- Proteomic techniques are valuable tools for COPD biomarker discovery.
- Identified potential biomarkers offer insights into COPD onset and progression mechanisms.
- Further research using these biomarkers can enhance understanding and management of COPD.
Related Concept Videos
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:33Proteomics
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...